Company Galmed Pharmaceuticals Ltd.

Equities

GLMD

IL0011313900

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Delayed Nasdaq Other stock markets 07:28:31 03/05/2024 pm IST			5-day change	1st Jan Change
0.39 ^USD	+1.27%		-0.41%	-14.29%

04/04	Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
15/03	Galmed Pharmaceuticals Ltd. Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of Nash and Liver Fibrosis	CI

Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).

Number of employees: 6

Managers	Title	Age	Since
Allen Baharaff CEO	Chief Executive Officer	59	01/00/01
Doron Cohen DFI	Director of Finance/CFO	57	01/22/01
Guy Nehemya COO	Chief Operating Officer	39	01/13/01
Liat Hayardeny CTO	Chief Tech/Sci/R&D Officer	57	07/16/07
Yohai Stenzler AUD	Comptroller/Controller/Auditor	41	01/14/01

Members of the board	Title	Age	Since
David Sidransky BRD	Director/Board Member	64	01/14/01
Carol Brosgart BRD	Director/Board Member	72	07/17/07
Allen Baharaff CEO	Chief Executive Officer	59	01/00/01
Shmuel Nir BRD	Director/Board Member	62	01/07/01
Amir Poshinski BRD	Director/Board Member	63	16/20/16

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	6,009,654	5,777,152 ( 96.13 %)	0	96.13 %

Name	Equities	%	Valuation
CVI Holdings LLC 7.072 %	269,238	7.072 %	93 156 $
Allen Baharaff 5.983 %	227,790	5.983 %	78 815 $
Walleye Capital LLC 3.031 %	115,400	3.031 %	39 928 $
Morgan Stanley Capital Services LLC 2.166 %	82,468	2.166 %	28 534 $
Two Sigma Advisers LP 1.167 %	44,433	1.167 %	15 374 $
Two Sigma Investments LP 0.6177 %	23,516	0.6177 %	8 137 $
Citadel Securities GP LLC 0.2955 %	11,251	0.2955 %	3 893 $
Shmuel Nir 0.0857 %	3,262	0.0857 %	1 129 $
David Sidransky 0.0131 %	500	0.0131 %	173 $
Yohai Stenzler 0.009850 %	375	0.009850 %	130 $

Galmed Pharmaceuticals Ltd.

16 Abba Hillel Road

5250608, Ramat Gan

+972 3 693 8448

http://galmedpharma.com

address Galmed Pharmaceuticals Ltd.(GLMD)

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.3851 USD

Average target price

1 USD

Spread / Average Target

+159.67%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
GALMED PHARMACEUTICALS LTD.	-14.29%	2.31M
VERTEX PHARMACEUTICALS INCORPORATED	-1.60%	103B
REGENERON PHARMACEUTICALS, INC.	+7.14%	101B
ARGENX SE	+4.37%	23.07B
BIONTECH SE	-13.09%	22.23B
GENMAB A/S	-4.97%	18.05B
WUXI APPTEC CO., LTD.	-39.98%	17.18B
BEIGENE, LTD.	-10.74%	16.94B
NEUROCRINE BIOSCIENCES, INC.	+6.57%	14.07B
SAREPTA THERAPEUTICS, INC.	+36.90%	12.35B

Bio Therapeutic Drugs